Drug exposure and psoriasis vulgaris: Case-control and case-crossover studies

Acta Dermato-Venereologica

Volumn 85, Issue 4, 2005, Pages 299-303

  Cohen, Arnon D ^a,b,c   Bonneh, Dan Y ^b   Reuveni, Haim ^b   Vardy, Daniel A ^b   Naggan, Lechaim ^b   Halevy, Sima ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c NONE   (Israel)

Author keywords

Angiotensin converting enzyme inhibitors; Beta blockers; Drug reactions; Non steroidal anti inflammatory drugs; Psoriasis vulgaris

Indexed keywords

ACETIC ACID DERIVATIVE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRONE; GOLD; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC NITRATE; PARACETAMOL; PENICILLIN DERIVATIVE; PROPIONIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MALE; PATIENT CARE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CROSS-OVER STUDIES; FEMALE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 23444448418     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550510032823     Document Type: Article

References (25)

1. Abel EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15: 1007-1022.
2. Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol 1992; 11: 269-274.
3. Gold MH, Holy AK, Roenigk HH Jr. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19: 837-841.
4. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000; 1: 159-165.
5. Cohen AD, Kagen M, Friger M, Halevy S. Calcium channel blockers intake and psoriasis: a case-control study. Acta Derm Venereol 2001; 81: 347-349.
6. Marshall RJ, Jackson RT. Analysis of case-crossover designs. Stat Med 1993; 12: 2333-2341.
7. Marshall RJ, Wouters S, Jackson RT. A case-crossover analysis of a case-control study of alcohol consumption and coronary events: the effects of exposure definition and the use of control data. J Epidemiol Biostat 2000; 5: 367-373.
8. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133: 144-153.
9. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221.
10. Gilleaudeau P, Vallat VP, Carter DM, Gottlieb AB. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993; 28: 490-492.
11. Wolf R, Dorfman B, Krakowski A. Psoriasiform eruption induced by captopril and chlorthalidone. Cutis 1987; 40: 162-164.
12. Ikai K. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1995; 32: 819.
13. Tamir A, Wolf R, Brenner S. Exacerbation and induction of psoriasis by angiotensin-converting enzyme inhibitors. J Am Acad Dermatol 1994; 30: 1045.
14. Coulter DM, Pillans PI. Angiotensin-converting enzyme inhibitors and psoriasis. N Z Med J 1993; 106: 392-393.
15. Steinkraus V, Steinfath M, Mensing H. Beta-adrenergic blocking drugs and psoriasis. J Am Acad Dermatol 1992; 27: 266-267.
16. Halevy S, Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism. J Am Acad Dermatol 1993; 29: 504-505.
17. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol - the role of an immunological mechanism. Arch Dermatol Res 1991; 283: 472-473.
18. Ferrier MC, Souteyrand P. Psoriasis and non steroidal anti-inflammatory agents. Ann Dermatol Venereol 1992; 119: 591-595.
19. Powles AV, Griffiths CE, Seifert MH, Fry L. Exacerbation of psoriasis by indomethacin. Br J Dermatol 1987; 117: 799-800.
20. Katayama H, Kawada A. Exacerbation of psoriasis induced by indomethacin. J Dermatol 1981; 8: 323-327.
21. Lazarova AZ, Tsankov NK, Zlatkov NB. Psoriasis induced by topically applied indomethacin. Clin Exp Dermatol 1989; 14: 260-261.
22. Ascari-Raccagni A, Baldari U, Rossi E, Alessandrini F. Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy. J Eur Acad Dermatol Venereol 2000; 14: 315-316.
23. Katz M, Seidenbaum M, Weinrauch L. Penicillin-induced generalized pustular psoriasis. J Am Acad Dermatol 1987; 17: 918-920.
24. Sidoroff A, Halevy S, Bowes-Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-119.
25. Koester H, Fikentscher R. Beta-hemolysing streptococci invasion of the pharynx in exanthematic psoriasis. Dermatol Monatsschr 1974; 160: 650-653.